Hanmi Pharmaceutical Receives Korean Approval for GLP-1 Obesity Drug 'Efweto Injection'; Aims to Supply Within the Year
Hanmi Pharmaceutical has received domestic marketing approval for 'Efweto Injection,' a new GLP-1-class obesity treatment. The company will begin launch preparations with the goal of supplying the Korean market within the year. Hanmi Pharmaceutical announced on the 7th that it received item approva

Hanmi Pharmaceutical has received domestic marketing approval for 'Efweto Injection,' a new GLP-1-class obesity treatment. The company will begin launch preparations with the goal of supplying the Korean market within the year.
Hanmi Pharmaceutical announced on the 7th that it received item approval from the Ministry of Food and Drug Safety for five dosages of 'Efweto Injection,' which contains epeglenatide as its active ingredient. The approved dosages are 2mg, 4mg, 6mg, 8mg, and 10mg per 0.5mL.
The approval is for chronic weight management in adult patients, and it was approved for use as an adjunct to a reduced-calorie diet and increased physical activity.
■ Eligible Patients: Obese Patients with BMI of 30 or Higher Without Diabetes
The approval covers obese patients with an initial body mass index (BMI) of 30 or higher who do not have diabetes. Overweight patients with a BMI of 27 or higher but below 30 are also eligible if they do not have diabetes and have at least one weight-related comorbidity, such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
■ 45th Domestically Developed New Drug… Applied with LAPSCOVERY Technology
Efweto Injection is a biopharmaceutical approved as the 45th domestically developed new drug. It incorporates 'LAPSCOVERY,' Hanmi Pharmaceutical's long-acting peptide and protein technology.
Hanmi Pharmaceutical applied for approval on December 17 of last year. Prior to that, on November 27 of last year, it was designated as a candidate for 'GIFT,' the Ministry of Food and Drug Safety's expedited review support program for global innovative products.
The company expects that this approval will provide a new treatment option for obese patients in Korea. It is preparing for the launch in line with the manufacturing and marketing approval, aiming to supply the product within the year. However, the specific launch date and sales price were not disclosed in this announcement.
[This article was written with AI assistance for informational purposes. Decisions on whether to use a medication should be made based on the approved labeling and the judgment of medical professionals. This article does not recommend buying or selling any specific stock, and investment decisions and any resulting responsibility lie with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


